GLP-1 Medications and Bone Health: What the Research Shows

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

If you have been researching GLP-1 medications, you may have come across questions about bone density. It is a real consideration, and it deserves a clear, honest answer grounded in the research, not in alarm or dismissal.

The short version: any significant weight loss can affect bone density, because your skeleton responds to the mechanical load your body places on it. GLP-1 medications are no exception to this principle. But the full picture is more nuanced than that, and understanding it helps you take practical steps to protect your skeletal health while you lose weight.

---

Why Weight Loss Affects Bone

Your bones are living tissue. They continuously remodel in response to stress and load. When you carry more body weight, your skeleton adapts by maintaining or increasing bone mineral density to handle that load. When you lose weight, the mechanical stimulus decreases, and bone remodeling can shift toward net loss at certain sites, particularly the hip.

This is not a side effect specific to GLP-1 medications. It happens with any effective weight loss strategy, including caloric restriction, bariatric surgery, and behavioral interventions. The faster and more substantial the weight loss, the more pronounced this effect can be.

A 2026 review published in *Endocrinology and Metabolism* summarized the current state of evidence clearly: intentional weight loss through caloric restriction or bariatric surgery consistently accelerates bone turnover and reduces bone mineral density, with surgical interventions showing the most significant impact. GLP-1 receptor agonists produce more modest changes, largely proportional to the degree of weight lost.

(Kim MJ, Cho YK. "Beyond Weight Loss: Skeletal Considerations in Obesity Treatment." *Endocrinol Metab (Seoul).* 2026 Apr 8. PMID: [41951103](https://pubmed.ncbi.nlm.nih.gov/41951103/))

---

What GLP-1 Research Shows About Bone

Several studies have now looked specifically at bone mineral density in people using semaglutide and tirzepatide.

The Weill Cornell study (2026). A team at New York Presbyterian Hospital and Weill Cornell Medical College conducted a retrospective study of 255 patients using semaglutide or tirzepatide for at least six months, compared to 255 matched controls. Both groups showed declines in bone mineral density at the total hip and femoral neck over a median follow-up of 17 months. In patients without diabetes, the GLP-1 group had slightly greater annualized total hip bone loss than controls (1% vs 0.6%). Importantly, weight loss was directly correlated with the degree of bone loss at the total hip and femoral neck, supporting the conclusion that weight reduction, not a direct drug effect, is the primary driver.

(Liu Y et al. "Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures." *J Clin Endocrinol Metab.* 2026 Feb 7. PMID: [41655226](https://pubmed.ncbi.nlm.nih.gov/41655226/))

The older adults pilot trial (2025). Researchers at Wake Forest University conducted a 20-week randomized pilot trial in older adults using semaglutide combined with lifestyle counseling versus lifestyle counseling alone. The semaglutide group lost significantly more weight. There were no statistically significant differences in whole-body bone mineral density or bone turnover markers between groups. The authors noted the study was small (20 participants) and called for further investigation.

(Dinkla L et al. "Bone mineral density and turnover response to GLP-1 receptor agonists in older adults." *Front Aging.* 2025;6:1691007. PMID: [41393101](https://pubmed.ncbi.nlm.nih.gov/41393101/))

The big picture on fracture risk. A 2026 systematic review and meta-analysis published in *Therapeutic Advances in Musculoskeletal Disease* analyzed 43 randomized controlled trials with more than 100,000 participants. It found no significant difference in osteoporotic fractures between GLP-1 receptor agonist users and controls across the RCT data. This is an important finding: at the level of clinical trials, increased fracture rates have not been a consistent or statistically significant signal.

(Cao M et al. "The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events." *Ther Adv Musculoskelet Dis.* 2026;18:1759720X261428147. PMID: [41782908](https://pubmed.ncbi.nlm.nih.gov/41782908/))

---

A Potentially Protective Signal

Here is where the story gets more interesting. GLP-1 receptors are not just found in the gut and pancreas. They are expressed in osteoblasts, the cells responsible for building new bone. Preclinical research suggests that GLP-1 signaling may have direct osteoanabolic effects, meaning it could support bone formation at the cellular level.

A 2021 review in the *International Journal of Molecular Sciences* examined incretin-related drugs and found that GLP-1 receptor agonists appear to enhance the expression of bone formation markers and may improve bone quality and density in preclinical models. GLP-1 may also exert anti-resorptive effects by suppressing inflammatory cytokines that promote bone breakdown.

(Kitaura H et al. "Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption." *Int J Mol Sci.* 2021;22(12):6578. PMID: [34205264](https://pubmed.ncbi.nlm.nih.gov/34205264/))

This does not mean GLP-1 medications protect your bones, and you should not interpret this research that way. Preclinical findings often do not translate directly to human outcomes. But it does suggest the relationship between GLP-1 and bone is not simply one of harm. The evidence points toward weight-loss-driven mechanical unloading as the primary concern, with some possibility of countervailing direct effects from the drug itself.

---

Who Should Pay Closer Attention

Bone density concerns are not equally distributed across everyone using GLP-1 medications. Certain groups face higher baseline risk and benefit most from proactive monitoring.

Postmenopausal women. Estrogen plays a key role in maintaining bone density. After menopause, declining estrogen accelerates bone loss, and the addition of weight-loss-related bone changes creates more cumulative risk. Women past menopause who are starting GLP-1 treatment should discuss bone health specifically with their provider.

Adults over 65. Age-related bone loss compounds with weight-loss-related changes. Older adults also have less reserve to absorb temporary increases in bone resorption.

Anyone with existing low bone density. If you have a prior diagnosis of osteopenia or osteoporosis, or a personal or family history of fragility fractures, bone monitoring is important before and during treatment.

Those on medications that affect bone. Certain medications, including corticosteroids and some anticonvulsants, affect bone density independently. Your provider needs to know your full medication list.

---

Practical Steps to Protect Your Bones

The good news is that you have real tools available to protect your skeletal health during GLP-1 treatment. None of these require elaborate interventions.

Resistance exercise. Strength training is the most effective lifestyle intervention for maintaining bone density during weight loss. Mechanical loading from resistance exercise signals your bones to maintain density even as body weight decreases. Aim for at least two to three sessions per week, focusing on weight-bearing and load-bearing movements. Speak with your provider before starting any new exercise program.

Adequate protein intake. Protein is essential for both muscle preservation and bone matrix. Weight loss on GLP-1 medications reduces appetite significantly, and some people inadvertently undereat protein. Current evidence supports prioritizing protein at every meal. Your provider or a registered dietitian can help you set a target appropriate for your body weight and goals.

Calcium and vitamin D. These are the foundational nutrients for bone health. Most adults need 1,000 to 1,200 mg of calcium daily from food sources, with supplementation to fill gaps. Vitamin D, which is necessary for calcium absorption, is commonly deficient. Your provider can check your vitamin D level and recommend an appropriate dose.

A baseline DEXA scan if indicated. A dual-energy X-ray absorptiometry scan measures bone mineral density at the hip and spine. If you are in a higher-risk category, asking your provider about a baseline scan before starting treatment gives you a reference point for monitoring over time.

---

When to Talk to Your Provider

You do not need to resolve bone health questions on your own. Your healthcare provider can review your personal risk factors, check relevant labs including vitamin D and calcium, and help you decide whether bone density monitoring makes sense for your situation.

If you experience any bone pain, a fracture, or unexpected musculoskeletal symptoms while on GLP-1 treatment, mention them at your next visit or contact your provider sooner.

---

The Bottom Line

GLP-1 medications like semaglutide and tirzepatide are associated with modest declines in bone mineral density, and the research consistently points to weight loss itself, rather than the medication's direct effects, as the primary driver. Large-scale randomized trial data have not shown an increase in fracture rates in GLP-1 users versus controls.

That does not mean you should ignore bone health during treatment. It means you should address it proactively with resistance exercise, adequate nutrition, and the right conversations with your provider. Managing bone health alongside your weight loss goals is not complicated, but it does require intention.

---

*This article does not constitute medical advice. Consult a licensed healthcare provider before beginning any medication or treatment program. Individual results vary. Compounded semaglutide and compounded tirzepatide are not FDA-approved.*